OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO(TM) and KEYTRUDA® Plus Chemotherapy
Stock Information for OncoSec Medical Incorporated
Loading
Please wait while we load your information from QuoteMedia.